TY - JOUR
T1 - Clinical characteristics and outcomes of heart failure with preserved ejection fraction
T2 - Lessons from epidemiological studies
AU - Tsutsui, Hiroyuki
AU - Tsuchihashi-Makaya, Miyuki
AU - Kinugawa, Shintaro
N1 - Funding Information:
The JCARE-CARD investigators and participating cardiologists are listed in the appendix of our previous publication [10] . This study could not have been carried out without the help, cooperation and support of the cardiologists in the participating institutions. We thank them for allowing us to obtain the data. The JCARE-CARD was supported by the Japanese Circulation Society and the Japanese Society of Heart Failure and by grants from Health Sciences Research Grants from the Japanese Ministry of Health, Labor and Welfare (Comprehensive Research on Cardiovascular Diseases), the Japan Heart Foundation , and Japan Arteriosclerosis Prevention Fund .
PY - 2010/1
Y1 - 2010/1
N2 - Recent epidemiological studies have demonstrated that nearly half of all patients with heart failure (HF) have preserved left ventricular ejection fraction (HFPEF). Compared to those with reduced EF, patients with HFPEF are older, more likely to be women, less likely to have coronary artery disease, and more likely to have hypertension and atrial fibrillation. Patients with HFPEF receive different pharmacological as well as nonpharmacological treatments from those with reduced EF. Morbidity and mortality in patients with HFPEF are largely similar to those with reduced EF. Although much information has recently been obtained about the clinical characteristics, medications, and outcomes of HFPEF by large-scale clinical and epidemiological studies, effective management strategies need to be established for this type of HF.
AB - Recent epidemiological studies have demonstrated that nearly half of all patients with heart failure (HF) have preserved left ventricular ejection fraction (HFPEF). Compared to those with reduced EF, patients with HFPEF are older, more likely to be women, less likely to have coronary artery disease, and more likely to have hypertension and atrial fibrillation. Patients with HFPEF receive different pharmacological as well as nonpharmacological treatments from those with reduced EF. Morbidity and mortality in patients with HFPEF are largely similar to those with reduced EF. Although much information has recently been obtained about the clinical characteristics, medications, and outcomes of HFPEF by large-scale clinical and epidemiological studies, effective management strategies need to be established for this type of HF.
UR - http://www.scopus.com/inward/record.url?scp=72449182112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72449182112&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2009.09.003
DO - 10.1016/j.jjcc.2009.09.003
M3 - Review article
C2 - 20122544
AN - SCOPUS:72449182112
SN - 0914-5087
VL - 55
SP - 13
EP - 22
JO - Journal of Cardiology
JF - Journal of Cardiology
IS - 1
ER -